APA

Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., Vey N., Recher C., Dartigeas C., Legros L., Delaunay J., Salanoubat C., Visanica S., Stamatoullas A., Isnard F., Marfaing-Koka A., de Botton S., Chelghoum Y., Taksin A., Plantier I., Ame S., Boehrer S., Gardin C., Beach C. L., Adès L. & Fenaux P. (20110223). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. : Blood.

Chicago

Itzykson Raphael, Thépot Sylvain, Quesnel Bruno, Dreyfus Francois, Beyne-Rauzy Odile, Turlure Pascal, Vey Norbert, Recher Christian, Dartigeas Caroline, Legros Laurence, Delaunay Jacques, Salanoubat Célia, Visanica Sorin, Stamatoullas Aspasia, Isnard Francoise, Marfaing-Koka Anne, de Botton Stephane, Chelghoum Youcef, Taksin Anne-Laure, Plantier Isabelle, Ame Shanti, Boehrer Simone, Gardin Claude, Beach C L, Adès Lionel and Fenaux Pierre. 20110223. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. : Blood.

Harvard

Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., Vey N., Recher C., Dartigeas C., Legros L., Delaunay J., Salanoubat C., Visanica S., Stamatoullas A., Isnard F., Marfaing-Koka A., de Botton S., Chelghoum Y., Taksin A., Plantier I., Ame S., Boehrer S., Gardin C., Beach C. L., Adès L. and Fenaux P. (20110223). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. : Blood.

MLA

Itzykson Raphael, Thépot Sylvain, Quesnel Bruno, Dreyfus Francois, Beyne-Rauzy Odile, Turlure Pascal, Vey Norbert, Recher Christian, Dartigeas Caroline, Legros Laurence, Delaunay Jacques, Salanoubat Célia, Visanica Sorin, Stamatoullas Aspasia, Isnard Francoise, Marfaing-Koka Anne, de Botton Stephane, Chelghoum Youcef, Taksin Anne-Laure, Plantier Isabelle, Ame Shanti, Boehrer Simone, Gardin Claude, Beach C L, Adès Lionel and Fenaux Pierre. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. : Blood. 20110223.